Icrucumab Biosimilar - Research Grade

Human

FLT1

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P17948

2321

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-VEGFR-1 antibody Icrucumab, supplied strictly for research use only. It is a human IgG1/kappa built around the target VEGFR-1 (FLT1), designed to reproduce the binding characteristics of the originator molecule so investigators can study receptor engagement and ligand-blocking in a defined reagent. It is not the clinical drug and is not intended for human or veterinary use. The material is offered at low endotoxin levels (research grade typically <1 EU/mg, with an ultra-low <0.5 EU/mg option) and in bulk milligram-to-gram quantities, making it suitable as a consistent, lot-controlled tool for both in-vitro and preclinical in-vivo work. Typical applications include positive/isotype-matched binding controls, neutralisation and receptor-blocking assays, standards for bioanalytical and pharmacokinetic method development, benchmarking of biosimilar or novel anti-angiogenic candidates, and as a building block for ADCC or antibody-drug-conjugate development workflows. Its recombinant, animal-component-defined production supports reproducibility across studies. VEGFR-1 (FLT1) is a class III receptor tyrosine kinase and a principal regulator of vascular development and angiogenesis. Its extracellular region comprises seven immunoglobulin-like domains that bind VEGF-A, VEGF-B and placental growth factor (PlGF), with the second and third Ig domains sufficient for high-affinity VEGF-A binding. VEGFR-1 has notably higher VEGF-A affinity than VEGFR-2 but comparatively weak intrinsic kinase activity, so it can act as a decoy or modulatory receptor that fine-tunes VEGF signalling toward VEGFR-2. A soluble splice variant (sFlt-1) sequesters circulating VEGF and is implicated in vascular homeostasis and preeclampsia. Beyond endothelium, VEGFR-1 is expressed on monocytes/macrophages and some tumour cells, contributing to inflammatory cell recruitment, tumour angiogenesis and metastatic niche formation, which underlies interest in it as an oncology and anti-angiogenic target.

VEGFR-1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, FLT, Vascular permeability factor receptor, Vascular endothelial growth factor receptor 1, FRT

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Icrucumab (anti-FLT1) Biosimilar

Q: Is the Icrucumab biosimilar available in bulk or gram quantities?

A: Yes — the Icrucumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Icrucumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Icrucumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Icrucumab that binds FLT1.